HRT Versus MOS for Endometrial Preparation Prior to FET in Non PCOS Patients

Overview

Evaluation of endometrial preparation using either hormonal therapy or ovarian stimulation prior to frozen-thawed embryo transfer (FET) in patients without polycystic ovarian syndrome (PCOS)

Full Title of Study: “Hormone Replacement Therapy Versus Minimal Ovarian Stimulation for Endometrial Preparation Prior to Frozen-thawed Embryo Transfer in Non Polycystic Ovarian Syndrome Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 31, 2024

Detailed Description

Women will be randomly divided into two groups; one will be subjected to endometrial preparation by hormone replacement therapy (HRT) and the other will be subjected to minimal ovarian stimulation (MOS). Women in the HRT group will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is < 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started. Women in the MOS group will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle > 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours. In both groups, FET will be planned in the appropriate day according to the stage that the embryos have been cryopreserved in it.

Interventions

  • Drug: Estradiol valerate
    • Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is < 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.
  • Drug: Sequential Clomiphene citrate and Gonadotropin
    • Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle > 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.

Arms, Groups and Cohorts

  • Active Comparator: HRT group
    • Women will be subjected to HRT using Estradiol valerate before FET
  • Active Comparator: MOS group
    • Women will be subjected to MOS using sequential clomiphene citrate and gonadotropin before FET

Clinical Trial Outcome Measures

Primary Measures

  • Clinical pregnancy rate
    • Time Frame: 6 weeks after embryo transfer
    • Number of clinical pregnancies (defined as presence of at least one intrauterine gestational sac with fetal pole and cardiac activity on TVS scan at 4-6 weeks after the ET) divided by the number of ET procedures

Secondary Measures

  • Implantation rate
    • Time Frame: 6 weeks after embryo transfer
    • Number of gestational sacs on TVS scan at 4-6 weeks after ET divided by the number of transferred embryos
  • Miscarriage rate
    • Time Frame: 12 weeks gestational age
    • Number of first trimester miscarriages (before 12 weeks gestational age) divided by the number of clinical pregnancies

Participating in This Clinical Trial

Inclusion Criteria

  • Women without PCOS as defined by the Rotterdam criteria. – Presence of at least 2 cryopreserved good quality cleavage-stage embryo (good quality cleavage-stage embryos display stage-specific cell division, have blastomeres of fairly equal size with few to no cytoplasmic fragments). Exclusion Criteria:

  • PCOS or polycystic ovary on ultrasound scan. – Moderate or severe endometriosis. – Hydrosalpinx. – Uterine abnormalities or myoma. – Previous uterine surgery.

Gender Eligibility: Female

Minimum Age: 20 Years

Maximum Age: 38 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Mansoura University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Mohamed Sayed Abdelhafez, Dr – Mansoura University
  • Overall Official(s)
    • Mohamed S Abdelhafez, Dr, Principal Investigator, Mansoura University
  • Overall Contact(s)
    • Mohamed S Abdelhafez, Dr, +201144523366, msabdelhafez@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.